These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 37348193)

  • 1. Demographic Features and Clinical Course of Patients With Pediatric-Onset Multiple Sclerosis on Newer Disease-Modifying Treatments.
    Malani Shukla N; Casper TC; Ness J; Wheeler Y; Chitnis T; Lotze T; Gorman M; Benson L; Weinstock-Guttmann B; Aaen G; Rodriguez M; Tillema JM; Krupp L; Schreiner T; Mar S; Goyal M; Rensel M; Abrams A; Rose J; Waltz M; Liu T; Manlius C; Waubant E;
    Pediatr Neurol; 2023 Aug; 145():125-131. PubMed ID: 37348193
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative effectiveness of dimethyl fumarate versus fingolimod and teriflunomide among MS patients switching from first-generation platform therapies in the US.
    Ontaneda D; Nicholas J; Carraro M; Zhou J; Hou Q; Babb J; Riester K; Mendoza JP; Livingston T; Jhaveri M
    Mult Scler Relat Disord; 2019 Jan; 27():101-111. PubMed ID: 30368221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative Effectiveness of Natalizumab, Fingolimod, and Injectable Therapies in Pediatric-Onset Multiple Sclerosis: A Registry-Based Study.
    Spelman T; Simoneau G; Hyde R; Kuhelj R; Alroughani R; Ozakbas S; Karabudak R; Yamout BI; Khoury SJ; Terzi M; Boz C; Horakova D; Kubala Havrdova E; Weinstock-Guttman B; Patti F; Altintas A; Mrabet S; Gouider R; Inshasi J; Shaygannejad V; Eichau S; Ward WL; Butzkueven H;
    Neurology; 2024 Apr; 102(7):e208114. PubMed ID: 38447093
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-World Effectiveness of Initial Disease-Modifying Therapies in Pediatric Multiple Sclerosis.
    Krysko KM; Graves JS; Rensel M; Weinstock-Guttman B; Rutatangwa A; Aaen G; Belman A; Benson L; Chitnis T; Gorman M; Goyal MS; Harris Y; Krupp L; Lotze T; Mar S; Moodley M; Ness J; Rodriguez M; Rose J; Schreiner T; Tillema JM; Waltz M; Casper TC; Waubant E;
    Ann Neurol; 2020 Jul; 88(1):42-55. PubMed ID: 32267005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of newer disease-modifying therapies in pediatric multiple sclerosis in the US.
    Krysko KM; Graves J; Rensel M; Weinstock-Guttman B; Aaen G; Benson L; Chitnis T; Gorman M; Goyal M; Krupp L; Lotze T; Mar S; Rodriguez M; Rose J; Waltz M; Charles Casper T; Waubant E;
    Neurology; 2018 Nov; 91(19):e1778-e1787. PubMed ID: 30333163
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiple Sclerosis in Children: Differential Diagnosis, Prognosis, and Disease-Modifying Treatment.
    Jakimovski D; Awan S; Eckert SP; Farooq O; Weinstock-Guttman B
    CNS Drugs; 2022 Jan; 36(1):45-59. PubMed ID: 34940954
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Newer disease modifying treatments in pediatric onset multiple sclerosis: Experience from a single center.
    Solmaz I; Acar Ozen P; Parlak S; Tuncer A; Anlar B
    Eur J Paediatr Neurol; 2022 Jul; 39():110-115. PubMed ID: 35777190
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trends in the use of disease-modifying therapies among reproductive-aged women with multiple sclerosis in the United States from 2010 to 2019.
    Duchesneau ED; Kinlaw AC; Jonsson Funk M; Pate V; Lund JL
    Pharmacoepidemiol Drug Saf; 2022 Apr; 31(4):481-487. PubMed ID: 35088492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fingolimod as a first- or second-line treatment in a mini-series of young Hellenic patients with adolescent-onset multiple sclerosis: focus on immunological data.
    Gontika M; Skarlis C; Markoglou N; Evangelopoulos ME; Velonakis G; Chrousos GP; Dalakas M; Stefanis L; Anagnostouli M
    Neurol Sci; 2022 Apr; 43(4):2641-2649. PubMed ID: 34596776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Compliance to fingolimod and other disease modifying treatments in multiple sclerosis patients, a retrospective cohort study.
    Agashivala N; Wu N; Abouzaid S; Wu Y; Kim E; Boulanger L; Brandes DW
    BMC Neurol; 2013 Oct; 13():138. PubMed ID: 24093542
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Initiation Patterns of Disease-Modifying Therapies for Multiple Sclerosis Among US Adults and Children, 2001 Through 2020.
    Henderson M; Horton DB; Bhise V; Pal G; Bushnell G; Dave CV
    JAMA Neurol; 2023 Aug; 80(8):860-867. PubMed ID: 37428482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative Effectiveness of Rituximab and Other Initial Treatment Choices for Multiple Sclerosis.
    Granqvist M; Boremalm M; Poorghobad A; Svenningsson A; Salzer J; Frisell T; Piehl F
    JAMA Neurol; 2018 Mar; 75(3):320-327. PubMed ID: 29309484
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pediatric-onset Multiple Sclerosis treatment: a multicentre observational study comparing natalizumab with fingolimod.
    Carotenuto A; Di Monaco C; Papetti L; Borriello G; Signoriello E; Masciulli C; Tomassini V; De Luca G; Ianniello A; Lus G; Novarella F; Spiezia AL; Di Somma D; Moccia M; Petracca M; Iacovazzo C; Servillo G; Portaccio E; Triassi M; Amato MP; Pozzilli C; Valeriani M; Brescia Morra V; Lanzillo R
    J Neurol; 2024 Oct; 271(10):6773-6781. PubMed ID: 39177751
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Persistence, adherence, healthcare resource utilization and costs for ocrelizumab in the real-world of the Campania Region of Italy.
    Moccia M; Affinito G; Berera G; Marrazzo G; Piscitelli R; Carotenuto A; Petracca M; Lanzillo R; Triassi M; Brescia Morra V; Palladino R
    J Neurol; 2022 Dec; 269(12):6504-6511. PubMed ID: 35953597
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Four-year safety and effectiveness data from patients with multiple sclerosis treated with fingolimod: The Spanish GILENYA registry.
    Meca-Lallana JE; Oreja-Guevara C; Muñoz D; Olascoaga J; Pato A; Ramió-Torrentà L; Meca-Lallana V; Hernández MA; Marzo ME; Álvarez-Cermeño JC; Rodríguez-Antigüedad A; Montalbán X; Fernández O;
    PLoS One; 2021; 16(10):e0258437. PubMed ID: 34644366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world disease-modifying therapy usage in persons with relapsing-remitting multiple sclerosis: Cross-sectional data from the Swiss Multiple Sclerosis Registry.
    Bossart J; Kamm CP; Kaufmann M; Stanikić M; Puhan MA; Kesselring J; Zecca C; Gobbi C; Rapold I; Kurmann R; Ammann S; von Wyl V;
    Mult Scler Relat Disord; 2022 Apr; 60():103706. PubMed ID: 35228114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Delayed initiation of disease modifying therapy increases relapse frequency and motor disability in pediatric onset multiple sclerosis.
    Jafarpour S; Pinto S; Vu MH; Khoshnood MM; Ahsan N; Saucier LE; Santoro JD
    Mult Scler Relat Disord; 2024 Jul; 87():105669. PubMed ID: 38749351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Persistence, Adherence, and Switching to Higher-Cost Therapy in Patients with Multiple Sclerosis Initiating Oral Disease-Modifying Therapies: A Retrospective Real-World Study.
    Araujo L; Geertsen SS; Amedume A; Higuchi K; van Wingerden J
    Neurol Ther; 2022 Dec; 11(4):1735-1748. PubMed ID: 36152222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiple Sclerosis, Disease-Modifying Therapies, and Infections.
    Langer-Gould AM; Smith JB; Gonzales EG; Piehl F; Li BH
    Neurol Neuroimmunol Neuroinflamm; 2023 Nov; 10(6):. PubMed ID: 37813594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. No evidence of disease activity in patients receiving fingolimod at private or academic centers in clinical practice: a retrospective analysis of the multiple sclerosis, clinical, and magnetic resonance imaging outcomes in the USA (MS-MRIUS) study.
    Zivadinov R; Khan N; Korn JR; Lathi E; Silversteen J; Calkwood J; Kolodny S; Silva D; Medin J; Weinstock-Guttman B;
    Curr Med Res Opin; 2018 Aug; 34(8):1431-1440. PubMed ID: 29648900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.